Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study

ConclusionsAI therapy increased joint pain and reduced HRQoL, mainly during the first year of treatment. Patients previously treated with tamoxifen experienced greater pain when they switched to AI therapy and had an excess risk of discontinuation during the first 12  months.Trial registrationClinicalTrials.gov: NCT03811509. Registered 28 January 2018-Retrospectively registered,https://clinicaltrials.gov/ct2/show/NCT03811509.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research